...
首页> 外文期刊>Journal of Bioscience and Bioengineering >Diagnosis and discrimination of autoimmune Graves' disease and Hashimoto's disease using thyroid-stimulating hormone receptor-containing recombinant proteoliposomes
【24h】

Diagnosis and discrimination of autoimmune Graves' disease and Hashimoto's disease using thyroid-stimulating hormone receptor-containing recombinant proteoliposomes

机译:含促甲状腺激素受体的重组蛋白脂质体对自身免疫性格雷夫斯病和桥本氏病的诊断和鉴别

获取原文
获取原文并翻译 | 示例
           

摘要

Graves' disease (GD) is an autoimmune disease of the thyroid gland caused by autoantibodies against thyroid-stimulating hormone receptor (TSHR). Currently, the diagnostic test for TSHR autoantibodies is based on an indirect competitive binding assay that measures the ability of TSHR autoantibodies to inhibit the binding of thyroid-stimulating hormone (TSH) to TSHR. Here, we have developed a specific and direct diagnostic method for autoantibodies in GD that incorporates immobilized TSHR-containing recombinant proteoliposomes into an enzyme-linked immunosorbent assay (ELISA). To reduce non-specific binding of autoantibodies to recombinant proteoliposomes, we investigated the effect of polyethylene glycol (PEG)-lipid on the binding of commercially available anti-TSHR antibodies (aTSHRAb). The incorporation of PEG-lipids into liposomes decreased non-specific binding, as compared to liposomes that did not contain PEG-lipids, and the addition of blocking reagents further decreased non-specific reactivity. aTSHRAb exhibited higher reactivity towards PEG-modified TSHR recombinant proteoliposomes than PEG-modified liposomes without TSHR (bare liposomes). Importantly, serum autoantibodies from patients with GD, which is associated with hyperthyroidism, exhibited remarkably specific binding to TSHR recombinant proteoliposomes. Serum autoantibodies from patients with Hashimoto's disease (HD), which is associated with hypothyroidism, also reacted specifically with proteoliposomal TSHR. These results suggest that immobilized TSHR recombinant proteoliposomes can serve as a direct diagnostic test for GD and HD. Furthermore, given that there is no competition test currently available for detecting autoantibodies in HD, the combination of TSHR recombinant proteoliposome ELISA and indirect competitive TSHR binding assay might be an effective way to discriminate between GD and HD.
机译:Graves病(GD)是由针对甲状腺刺激激素受体(TSHR)的自身抗体引起的甲状腺自身免疫性疾病。目前,TSHR自身抗体的诊断测试基于间接竞争结合测定法,该测定法测量TSHR自身抗体抑制甲状腺刺激激素(TSH)与TSHR结合的能力。在这里,我们已经开发了一种针对GD中自身抗体的特定且直接的诊断方法,该方法将固定化的含TSHR的重组蛋白脂质体整合到酶联免疫吸附测定(ELISA)中。为了减少自身抗体与重组蛋白脂质体的非特异性结合,我们研究了聚乙二醇(PEG)-脂质对市售抗TSHR抗体(aTSHRAb)结合的影响。与不包含PEG-脂质的脂质体相比,将PEG-脂质掺入脂质体降低了非特异性结合,并且添加了封闭剂进一步降低了非特异性反应性。与没有TSHR的PEG修饰脂质体(裸脂质体)相比,aTSHRAb对PEG修饰的TSHR重组蛋白脂质体具有更高的反应性。重要的是,与甲状腺功能亢进有关的GD患者血清自身抗体表现出与TSHR重组蛋白脂质体的特异性结合。患有甲状腺功能减退症的桥本氏病(HD)患者的血清自身抗体也与蛋白脂质体TSHR发生特异性反应。这些结果表明,固定化的TSHR重组蛋白脂质体可以作为GD和HD的直接诊断测试。此外,鉴于目前尚无可用于检测HD中自身抗体的竞争性测试,TSHR重组蛋白脂质体ELISA和间接竞争性TSHR结合测定的组合可能是区分GD和HD的有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号